Acquiring Company
GSK plc
Acquired Company
Siran Biotechnology
Description
GSK has acquired Siran Biotechnology for over $1 billion to enhance its investigational siRNA therapy for metabolic diseases. The deal includes access to SiranBio's SA030, targeting the ALK7 receptor, which has potential benefits for weight management. This acquisition aligns with GSK's strategy to address health issues related to obesity and metabolism.
Quick answer
GSK plc is acquiring Siran Biotechnology for $1 billion, announced May 7, 2026.
- How much did GSK plc pay for Siran Biotechnology?
- The reported deal value is $1 billion.
- What does GSK plc do?
- GSK plc is a global healthcare company that researches and develops innovative pharmaceutical products, including vaccines.
- Where are GSK plc and Siran Biotechnology based?
- Siran Biotechnology is based in China.
- Who are the decision-makers at GSK plc?
- Fundz holds 4 contacts at GSK plc. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Pharmaceutical and Manufacturing
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- ESTEVE acquires TerSera's Infusion Business Unit (May 4, 2026)
- Laprophan Acquires Rivopharm for European Expansion (June 17, 2026)
- GSK to acquire Nuvalent for $10.6 billion, $11B (June 9, 2026)
- Assertio acquires Garda Therapeutics in merger deal (May 5, 2026)
- Eli Lilly to acquire Ajax Therapeutics for $2.3B, $2.3B (April 27, 2026)
- Anlon Healthcare acquires Remember India Health Links (April 16, 2026)
Who to call at GSK plc, and when
When GSK plc changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day GSK plc raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at GSK plc, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at GSK plc. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment GSK plc makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Siran Biotechnology?
Siran Biotechnology was acquired by GSK plc. The deal was reported on May 7, 2026. GSK plc is a global healthcare company that researches and develops innovative pharmaceutical products, including vaccines. GSK plc is publicly traded (GSK) and operates in Manufacturing.
When did GSK plc acquire Siran Biotechnology?
GSK plc's acquisition of Siran Biotechnology was reported on May 7, 2026. GSK has acquired Siran Biotechnology for over $1 billion to enhance its investigational siRNA therapy for metabolic diseases. The deal includes access to SiranBio's SA030, targeting the ALK7 receptor, which has potential benefits for weight management. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Siran Biotechnology do?
Siran Biotechnology is a company specializing in RNA development, specifically focused on siRNA therapies for various metabolic diseases. The company is dedicated to advancing innovative solutions targeting cardiovascular and metabolic health issues. It is privately held, and is based in China.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.